piracetam has been researched along with Body Weight in 23 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the efficacy and safety of 3,000 mg daily levetiracetam (LEV; Keppra) as an adjunctive therapy for Chinese patients with refractory partial seizures." | 9.14 | Efficacy and safety of levetiracetam (3,000 mg/Day) as an adjunctive therapy in Chinese patients with refractory partial seizures. ( Li, JM; Lv, Y; Sun, HB; Wang, XF; Xi, ZQ; Xiao, F; Xiao, Z, 2009) |
| "Levetiracetam (LEV) is commonly used as a mono- or adjunctive therapy for treating patients with partial and generalized epilepsy." | 7.85 | Population pharmacokinetics and dose-response relationship of levetiracetam in adult patients with epilepsy. ( Chu, K; Jang, IJ; Jung, KH; Jung, KY; Kim, TJ; Lee, S; Lee, SK; Lee, ST; Moon, J; Park, KI; Rhee, SJ; Shin, JW; Yu, KS, 2017) |
| "Body weight was measured at baseline and at the final LEV study visit." | 7.80 | Levetiracetam does not alter body weight: analysis of randomized, controlled clinical trials. ( Gidal, BE; Herbeuval, AF; Magnus, L; Sheth, RD, 2003) |
| "The pharmacokinetics of levetiracetam were determined prospectively in 18 neonates with seizures." | 7.77 | Pharmacokinetics of levetiracetam in neonates with seizures. ( Balmakund, T; Meinzen-Derr, J; Merhar, SL; Schibler, KR; Sherwin, CM; Shi, J; Vinks, AA, 2011) |
| "It is not known whether the antiepileptic drug (AED) levetiracetam can be used safely in human pregnancy." | 7.73 | Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. ( Craig, J; Guthrie, E; Hunt, S; Irwin, B; Morrison, PJ; Morrow, J; Parsons, L; Robertson, I; Russell, A; Waddell, R, 2006) |
| "To evaluate the efficacy and safety of 3,000 mg daily levetiracetam (LEV; Keppra) as an adjunctive therapy for Chinese patients with refractory partial seizures." | 5.14 | Efficacy and safety of levetiracetam (3,000 mg/Day) as an adjunctive therapy in Chinese patients with refractory partial seizures. ( Li, JM; Lv, Y; Sun, HB; Wang, XF; Xi, ZQ; Xiao, F; Xiao, Z, 2009) |
| "Data were pooled from ten matched clinical trials conducted in Japan and in Europe and the USA, in which levetiracetam was administered orally to healthy subjects and subjects with epilepsy." | 4.84 | Population pharmacokinetics of levetiracetam in Japanese and Western adults. ( Jacqmin, P; Pigeolet, E; Sargentini-Maier, ML; Stockis, A, 2007) |
| "Levetiracetam (LEV) is commonly used as a mono- or adjunctive therapy for treating patients with partial and generalized epilepsy." | 3.85 | Population pharmacokinetics and dose-response relationship of levetiracetam in adult patients with epilepsy. ( Chu, K; Jang, IJ; Jung, KH; Jung, KY; Kim, TJ; Lee, S; Lee, SK; Lee, ST; Moon, J; Park, KI; Rhee, SJ; Shin, JW; Yu, KS, 2017) |
| "Levetiracetam, a second-generation antiepileptic drug, is frequently used for managing partial-onset seizures." | 3.83 | Population Pharmacokinetic Modeling of Levetiracetam in Pediatric and Adult Patients With Epilepsy by Using Routinely Monitored Data. ( Hashi, S; Ikeda, A; Ito, S; Matsubara, K; Sugimoto, M; Tsuda, M; Yano, I; Yonezawa, A, 2016) |
| "The alterations observed in body composition with valproic acid in contrast to other AEDs like levetiracetam, carbamazepine and phenytoin could affect treatment response in epilepsy especially in subjects with already altered body composition status like obese and thin frail patients, which needs to be established by prospective studies (CTRI/2013/05/003701)." | 3.83 | Comparison of body composition in persons with epilepsy on conventional & new antiepileptic drugs. ( Gupta, YK; Kakkar, AK; Sarangi, SC; Tripathi, M, 2016) |
| " The treatment was given 1 and 5 min after exposure to a supralethal dose of nerve agents, and the results showed that the triple regimen successfully prevented or terminated seizures and preserved the lives of rats exposed to 5×LD50 of soman, sarin, cyclosarin, or VX, but solely 3×LD50 of tabun was managed by this regimen." | 3.81 | Supralethal poisoning by any of the classical nerve agents is effectively counteracted by procyclidine regimens in rats. ( Aas, P; Enger, S; Mariussen, E; Myhrer, T, 2015) |
| "Body weight was measured at baseline and at the final LEV study visit." | 3.80 | Levetiracetam does not alter body weight: analysis of randomized, controlled clinical trials. ( Gidal, BE; Herbeuval, AF; Magnus, L; Sheth, RD, 2003) |
| "The pharmacokinetics of levetiracetam were determined prospectively in 18 neonates with seizures." | 3.77 | Pharmacokinetics of levetiracetam in neonates with seizures. ( Balmakund, T; Meinzen-Derr, J; Merhar, SL; Schibler, KR; Sherwin, CM; Shi, J; Vinks, AA, 2011) |
| "It is not known whether the antiepileptic drug (AED) levetiracetam can be used safely in human pregnancy." | 3.73 | Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. ( Craig, J; Guthrie, E; Hunt, S; Irwin, B; Morrison, PJ; Morrow, J; Parsons, L; Robertson, I; Russell, A; Waddell, R, 2006) |
| "Piracetam (PIR) and dimethylaminoethanol (DMAE) were tested with respect to their ability to prevent changes of the locomotor behaviour and of the dopamine release from striatum slices after an intermittent postnatal hypoxia in the rat (2nd-10th day of postnatal life)." | 3.67 | Effects of nootropic drugs on some behavioural and biochemical changes after early postnatal hypoxia in the rat. ( Fischer, HD; Gramatté, T; Schmidt, J; Wustmann, C, 1986) |
| "Levetiracetam is an antiepileptic drug approved for use as an adjunct agent in partial-onset seizures in adults and children aged > or = 4 years." | 2.44 | The safety of levetiracetam. ( Safdieh, JE; Sirsi, D, 2007) |
| " The results suggest that the long-term administration of LEV in the model of gonadally intact rats does not have a negative effect on bone." | 1.48 | The effect of levetiracetam on rat bone mineral density, bone structure and biochemical markers of bone metabolism. ( Fekete, S; Karesova, I; Malakova, J; Palicka, V; Pavlikova, L; Simko, J; Zimcikova, E; Zivna, H, 2018) |
| "If the seizures also enhance the survival of neurons that are destined to undergo naturally occurring PCD, early childhood seizures may have deleterious effects by preventing this necessary component of normal development." | 1.34 | Neurodevelopmental impact of antiepileptic drugs and seizures in the immature brain. ( Gale, K; Kim, JS; Kondratyev, A; Tomita, Y, 2007) |
| "Levetiracetam (LEV) is a new antiepileptic drug approved as add-on therapy." | 1.32 | Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication. ( Jürgens, U; May, TW; Rambeck, B, 2003) |
| "Piracetam was shown to prevent completely behavioural disturbances and deficiency of GABA-ergic processes in grown-up animals." | 1.27 | [Piracetam correction of deficient GABA-ergic inhibition due to early postnatal exposure to cycloheximide]. ( Burov, IuV; Molodavkin, GM; Ostrovskaia, RU; Smol'nikova, NM; Trofimov, SS, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (21.74) | 18.7374 |
| 1990's | 1 (4.35) | 18.2507 |
| 2000's | 11 (47.83) | 29.6817 |
| 2010's | 6 (26.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Karesova, I | 1 |
| Simko, J | 1 |
| Fekete, S | 1 |
| Zimcikova, E | 1 |
| Malakova, J | 1 |
| Zivna, H | 1 |
| Pavlikova, L | 1 |
| Palicka, V | 1 |
| Myhrer, T | 1 |
| Mariussen, E | 1 |
| Enger, S | 1 |
| Aas, P | 1 |
| Ito, S | 1 |
| Yano, I | 1 |
| Hashi, S | 1 |
| Tsuda, M | 1 |
| Sugimoto, M | 1 |
| Yonezawa, A | 1 |
| Ikeda, A | 1 |
| Matsubara, K | 1 |
| Sarangi, SC | 1 |
| Tripathi, M | 1 |
| Kakkar, AK | 1 |
| Gupta, YK | 1 |
| Rhee, SJ | 1 |
| Shin, JW | 1 |
| Lee, S | 1 |
| Moon, J | 1 |
| Kim, TJ | 1 |
| Jung, KY | 1 |
| Park, KI | 1 |
| Lee, ST | 1 |
| Jung, KH | 1 |
| Yu, KS | 1 |
| Jang, IJ | 1 |
| Chu, K | 1 |
| Lee, SK | 1 |
| Xiao, Z | 1 |
| Li, JM | 1 |
| Wang, XF | 1 |
| Xiao, F | 1 |
| Xi, ZQ | 1 |
| Lv, Y | 1 |
| Sun, HB | 1 |
| Merhar, SL | 1 |
| Schibler, KR | 1 |
| Sherwin, CM | 1 |
| Meinzen-Derr, J | 1 |
| Shi, J | 1 |
| Balmakund, T | 1 |
| Vinks, AA | 1 |
| Zarubina, IV | 2 |
| Hadjikoutis, S | 1 |
| Pickersgill, TP | 1 |
| Smith, PE | 1 |
| May, TW | 1 |
| Rambeck, B | 1 |
| Jürgens, U | 1 |
| Gidal, BE | 1 |
| Sheth, RD | 1 |
| Magnus, L | 1 |
| Herbeuval, AF | 1 |
| Shabanov, PD | 1 |
| Hunt, S | 1 |
| Craig, J | 1 |
| Russell, A | 1 |
| Guthrie, E | 1 |
| Parsons, L | 1 |
| Robertson, I | 1 |
| Waddell, R | 1 |
| Irwin, B | 1 |
| Morrison, PJ | 1 |
| Morrow, J | 1 |
| Sirsi, D | 1 |
| Safdieh, JE | 1 |
| Pigeolet, E | 1 |
| Jacqmin, P | 1 |
| Sargentini-Maier, ML | 1 |
| Stockis, A | 1 |
| Kim, JS | 1 |
| Kondratyev, A | 1 |
| Tomita, Y | 1 |
| Gale, K | 1 |
| Mikati, MA | 1 |
| El Banna, D | 1 |
| Sinno, D | 1 |
| Mroueh, S | 1 |
| Jänicke, B | 2 |
| Wrobel, D | 1 |
| Martí Viaño, JL | 1 |
| Sellés, J | 1 |
| Orts, A | 1 |
| Marco, J | 1 |
| Vega, F | 1 |
| Esplugues, J | 1 |
| Coper, H | 1 |
| Burov, IuV | 1 |
| Ostrovskaia, RU | 1 |
| Smol'nikova, NM | 1 |
| Trofimov, SS | 1 |
| Molodavkin, GM | 1 |
| Gramatté, T | 1 |
| Wustmann, C | 1 |
| Schmidt, J | 1 |
| Fischer, HD | 1 |
| Platt, D | 1 |
| Mühlberg, W | 1 |
| Rieck, W | 1 |
3 reviews available for piracetam and Body Weight
| Article | Year |
|---|---|
Levetiracetam does not alter body weight: analysis of randomized, controlled clinical trials.
Topics: Adult; Anticonvulsants; Body Weight; Epilepsy; Europe; Female; Humans; Levetiracetam; Male; Piraceta | 2003 |
The safety of levetiracetam.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Blood Cells; Body Weight; Child; Child Behavior; Drug Hype | 2007 |
Population pharmacokinetics of levetiracetam in Japanese and Western adults.
Topics: Administration, Oral; Anticonvulsants; Body Weight; Cytochrome P-450 Enzyme System; Drug Administrat | 2007 |
3 trials available for piracetam and Body Weight
| Article | Year |
|---|---|
Efficacy and safety of levetiracetam (3,000 mg/Day) as an adjunctive therapy in Chinese patients with refractory partial seizures.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Anticonvulsants; Body Weight; Chemotherapy, Adjuvant; | 2009 |
Levetiracetam does not alter body weight: analysis of randomized, controlled clinical trials.
Topics: Adult; Anticonvulsants; Body Weight; Epilepsy; Europe; Female; Humans; Levetiracetam; Male; Piraceta | 2003 |
Response of infantile spasms to levetiracetam.
Topics: Anticonvulsants; Body Weight; Brain; Deglutition Disorders; Dose-Response Relationship, Drug; Drug A | 2008 |
18 other studies available for piracetam and Body Weight
| Article | Year |
|---|---|
The effect of levetiracetam on rat bone mineral density, bone structure and biochemical markers of bone metabolism.
Topics: Animals; Biomarkers; Biomechanical Phenomena; Body Weight; Bone Density; Femur; Levetiracetam; Lumba | 2018 |
Supralethal poisoning by any of the classical nerve agents is effectively counteracted by procyclidine regimens in rats.
Topics: Animals; Anticonvulsants; Antidotes; Body Weight; Brain; Disease Models, Animal; Dose-Response Relat | 2015 |
Population Pharmacokinetic Modeling of Levetiracetam in Pediatric and Adult Patients With Epilepsy by Using Routinely Monitored Data.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anticonvulsants; Body Weight; Child; Child, | 2016 |
Comparison of body composition in persons with epilepsy on conventional & new antiepileptic drugs.
Topics: Adult; Anticonvulsants; Benzodiazepines; Body Composition; Body Water; Body Weight; Carbamazepine; C | 2016 |
Population pharmacokinetics and dose-response relationship of levetiracetam in adult patients with epilepsy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Body Weight; Dose-Response Relationship | 2017 |
Pharmacokinetics of levetiracetam in neonates with seizures.
Topics: Anticonvulsants; Body Weight; Chromatography, Liquid; Creatinine; Female; Half-Life; Humans; Infant, | 2011 |
Drug correction of behavioral reactions and metabolic disorders in rats with craniocerebral trauma.
Topics: Animals; Antioxidants; Benzimidazoles; Body Weight; Brain; Brain Injuries; Carbon Tetrachloride Pois | 2003 |
Drug points: Weight loss associated with levetiracetam.
Topics: Adult; Anticonvulsants; Body Weight; Epilepsy; Female; Humans; Levetiracetam; Male; Middle Aged; Pir | 2003 |
Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication.
Topics: Adolescent; Adult; Age Factors; Aged; Anticonvulsants; Body Weight; Child; Child, Preschool; Dose-Re | 2003 |
The significance of individual resistance to hypoxia for correction of the consequences of craniocerebral trauma.
Topics: Animals; Antioxidants; Behavior, Animal; Benzimidazoles; Body Temperature; Body Weight; Brain Edema; | 2005 |
Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Body Weight; Epilepsy; Female; Humans; Infant, | 2006 |
Neurodevelopmental impact of antiepileptic drugs and seizures in the immature brain.
Topics: Animals; Animals, Newborn; Anticonvulsants; Apoptosis; Basal Ganglia; Behavior, Animal; Body Weight; | 2007 |
Changes in motor activity with age and the effects of pharmacologic treatment.
Topics: Aging; Animals; Body Weight; Dextroamphetamine; Dihydroergotoxine; Female; Meclofenoxate; Motor Acti | 1984 |
[Antagonism of barbituric coma by stimulating products. Experimental study].
Topics: Animals; Body Weight; Choline; Coma; Cytidine Diphosphate Choline; Female; Glycolates; Injections, I | 1978 |
Effects of age and drugs on food and fluid intake.
Topics: Aging; Amphetamines; Animals; Behavior, Animal; Benzodiazepines; Body Weight; Diazepam; Drinking; Dr | 1991 |
[Piracetam correction of deficient GABA-ergic inhibition due to early postnatal exposure to cycloheximide].
Topics: Animals; Body Weight; Conditioning, Classical; Cycloheximide; Escape Reaction; Isotonic Solutions; L | 1986 |
Effects of nootropic drugs on some behavioural and biochemical changes after early postnatal hypoxia in the rat.
Topics: Animals; Body Weight; Corpus Striatum; Deanol; Dopamine; Ethanolamines; Female; Hypoxia; In Vitro Te | 1986 |
The effect of age on clinical pharmacokinetics of piracetam.
Topics: Adult; Aged; Aging; Blood Proteins; Body Weight; Erythrocytes; Female; Half-Life; Humans; Kinetics; | 1985 |